Mystic Holdings Past Earnings Performance
Past criteria checks 0/6
Mystic Holdings's earnings have been declining at an average annual rate of -34.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 9.8% per year.
Key information
-34.8%
Earnings growth rate
-23.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 9.8% |
Return on equity | -48.2% |
Net Margin | -45.1% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Mystic Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 19 | -9 | 15 | 0 |
31 Mar 24 | 18 | -7 | 14 | 0 |
31 Dec 23 | 17 | -5 | 12 | 0 |
30 Sep 23 | 15 | -3 | 8 | 0 |
30 Jun 23 | 12 | -2 | 5 | 0 |
31 Mar 23 | 11 | -2 | 5 | 0 |
31 Dec 22 | 10 | -3 | 6 | 0 |
30 Sep 22 | 11 | 0 | 6 | 0 |
30 Jun 22 | 11 | -1 | 9 | 0 |
31 Mar 22 | 13 | -1 | 8 | 0 |
31 Dec 21 | 14 | -2 | 8 | 0 |
30 Sep 21 | 15 | -4 | 9 | 0 |
30 Jun 21 | 15 | -3 | 8 | 0 |
31 Mar 21 | 14 | -2 | 7 | 0 |
31 Dec 20 | 13 | -1 | 5 | 0 |
30 Sep 20 | 11 | -1 | 4 | 0 |
30 Jun 20 | 8 | -2 | 2 | 0 |
31 Mar 20 | 6 | -2 | 2 | 0 |
31 Dec 19 | 4 | -2 | 1 | 0 |
31 Dec 18 | 4 | -2 | 1 | 0 |
31 Dec 17 | 1 | -1 | 1 | 0 |
Quality Earnings: MSTH is currently unprofitable.
Growing Profit Margin: MSTH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MSTH is unprofitable, and losses have increased over the past 5 years at a rate of 34.8% per year.
Accelerating Growth: Unable to compare MSTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSTH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: MSTH has a negative Return on Equity (-48.25%), as it is currently unprofitable.